Pfizer, Inc. (NYSE:PFE)

bondmanbrown (60.85) Submitted: 2/19/2008 1:33:07 PM : Start Price: $18.40 PFE Score: +10.51

Pharmaceutical industry has been hit with downward pressure from products coming off-patent for the last few years.

They are sitting on 20 billion dollars in cash in case things get tough in the upcoming year. This cash could easily be used to buy a bio-tech firm as well.

41 consecutive years of increased dividends. There is plenty of incentive to wait for the next blockbuster drug to come from Pfizer. Healthcare is a trend that will never end.

This is a good play keeping future trends in mind because the baby boomer generation is getting older and healthcare demand and demand for new drugs in general will only increase. It is also interesting to consider the positive impact on sales both Obama and Hillary’s universal healthcare plans will have when implemented.

Undervalued, Unpopular & excellent dividends.